Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.
Daruka MahadevanMonica MitaDonald RichardsEdward McClayRebecca Suk HeistA KumarS SundararajanAung NaingPublished in: Cancer chemotherapy and pharmacology (2017)
Pimasertib tablet was overall well tolerated, had a similar safety and efficacy profile to standard capsule formulation and had bioavailability comparable to capsule.